ARTICLE | Company News

Immutep, Prima BioMed deal

January 5, 2015 8:00 AM UTC

Prima BioMed completed its acquisition of Immutep for up to $25 million in cash, shares and warrants. Prima BioMed attributed the difference from the original $28 million price “to the reduction in value of the warrants based on the Black Scholes option pricing model” (see BioCentury, Oct. 20, 2014). ...